Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience

References

• Sur DK, Scandale S. Treatment of allergic rhinitis. Am Fam Physician 2010;81:1440-6
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Blaiss MS, Naclerio RM, et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc 2012;33(Suppl 1):S113-41
   PubMedGoogle Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122:S1-84
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-334
   PubMed Web of Science ®Google Scholar
• Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis 2012;6:11-23
   PubMed Web of Science ®Google Scholar
• Moingeon P, Hrabina M, Bergmann KC, et al. Specific immunotherapy for common grass pollen allergies: pertinence of a five grass pollen vaccine. Int Arch Allergy Immunol 2008;146:338-42
   PubMed Web of Science ®Google Scholar
• Valovirta E. EFA book on respiratory allergies. 2011. Available from: www.theipcrg.org/download/attachments/689587/EFABookonRespiratoryAllergiesFINAL.pdf?version=1&modificationDate=1332965739000 [Last accessed 2 April 2014]
   Google Scholar
• Sih T, Mion O. Allergic rhinitis in the child and associated comorbidities. Pediatr Allergy Immunol 2010;21:e107-13
   PubMed Web of Science ®Google Scholar
• Uzzaman A, Story R. Chapter 5: allergic rhinitis. Allergy Asthma Proc 2012;33 Suppl 1:S15-18
   PubMedGoogle Scholar
• World Allergy Organization. WAO white book on allergy update 2013. World Allergy Organization; Milwaukee, WI: 2014
   Google Scholar
• Kirmaz C, Aydemir O, Bayrak P, et al. Sexual dysfunction in patients with allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2005;95:525-9
   PubMed Web of Science ®Google Scholar
• Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 2008;29:600-8
   PubMed Web of Science ®Google Scholar
• Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2011;11:471-6
   PubMed Web of Science ®Google Scholar
• Williams DC, Edney G, Maiden B, Smith PK. Recognition of allergic conjunctivitis in patients with allergic rhinitis. World Allergy Organ J 2013;6:4
   PubMedGoogle Scholar
• Tsilochristou OA, Douladiris N, Makris M, Papadopoulos NG. Pediatric allergic rhinitis and asthma: can the march be halted? Paediatr Drugs 2013;15:431-40
   PubMed Web of Science ®Google Scholar
• Turner PJ, Kemp AS. Allergic rhinitis in children. J Paediatr Child Health 2012;48:302-10
   PubMedGoogle Scholar
• Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010;40:385-97
   PubMed Web of Science ®Google Scholar
• Incorvaia C. Preventive capacity of allergen immunotherapy on the natural history of allergy. J Prev Med Hyg 2013;54:71-4
   PubMedGoogle Scholar
• Viswanathan RK, Busse WW. Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses. Chest 2012;141:1303-14
   PubMed Web of Science ®Google Scholar
• Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: world Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:6
   Google Scholar
• Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-3
   PubMed Web of Science ®Google Scholar
• Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007(1):CD001936
   PubMed Web of Science ®Google Scholar
• Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2014;124:616-27
   PubMed Web of Science ®Google Scholar
• Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010;125:569-74. e561-574
   PubMed Web of Science ®Google Scholar
• Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302-11
   PubMed Web of Science ®Google Scholar
• Devillier P, Dreyfus JF, Demoly P, Calderon MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med 2014;12:71
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013;43:568-77
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Sublingual five-grass pollen tablets (Oralair®): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis. Drugs Ther Perspect 2014; doi; 10.1007/s40267-40014-40131-40267
   Google Scholar
• ORALAIR® Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use: food and Drug Administration Allergenic Products Advisory Committee Briefing Document. Stallergènes S.A., 2013. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/AllergenicProductsAdvisoryCommittee/UCM377851.pdf [Last accessed 16 April 2014]
   Google Scholar
• Cox LS, Hankin C, Lockey R. Allergy immunotherapy adherence and delivery route: location does not matter. J Allergy Clin Immunol Pract 2014;2:156-60
   PubMed Web of Science ®Google Scholar
• Pajno GB, Vita D, Caminiti L, et al. Children’s compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 2005;116:1380-1
   PubMed Web of Science ®Google Scholar
• Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013;309:1278-88
   PubMed Web of Science ®Google Scholar
• Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010(12):CD002893
   PubMed Web of Science ®Google Scholar
• Sublingual immunotherapy for allergic rhinitis. Creticos PS, 2014. Available from: www.uptodate.com/contents/sublingual-immunotherapy-for-allergic-rhinitis [Last accessed 10 May 2014]
   Google Scholar
• Moingeon P, Peltre G, Bergmann KC. Rationale for a five-grass pollen vaccine. Clin Exp Allerg Rev 2008;8:12-14
   Google Scholar
• Summary of Product Characteristics: Oralair® 100 IR & 300 IR sublingual tablets. Stallergènes S.A., 2013. Available from: http://www.stallergenes.com/fileadmin/images/corporate/Emmanuelle/Oralair_SmPC.pdf [Last accessed 1 September 2014]
   Google Scholar
• US Prescribing Information: Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) Tablet for Sublingual Use. Stallergènes S.A., 2014. Available from: http://oralair.com/docs/ORALAIR%20Prescribing%20Information-Med%20Guide.pdf [Last accessed 11 May 2014]
   Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717-25
   PubMed Web of Science ®Google Scholar
• US Prescribing Information: Grastek® (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use. ALK-Abello/Merck, 2014. Available from: http://www.merck.com/product/usa/pi_circulars/g/grastek/grastek_pi.pdf [Last accessed 11 May 2014]
   Google Scholar
• Kaul S, May S, Luttkopf D, Vieths S. Regulatory environment for allergen-specific immunotherapy. Allergy 2011;66:753-64
   PubMed Web of Science ®Google Scholar
• Chabre H, Gouyon B, Huet A, et al. Molecular variability of group 1 and 5 grass pollen allergens between Pooideae species: implications for immunotherapy. Clin Exp Allergy 2010;40:505-19
   PubMed Web of Science ®Google Scholar
• Köberlein J, Mösges R. Oralair®: a causal treatment for grass pollen-induced allergic rhinoconjunctivitis. Immunotherapy 2013;5:13-21
   PubMed Web of Science ®Google Scholar
• Hong J, Bielory L. Oralair®: sublingual immunotherapy for the treatment of grass pollen allergic rhinoconjunctivitis. Expert Rev Clin Immunol 2011;7:437-44
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45
   PubMed Web of Science ®Google Scholar
• Archila LD, DeLong JH, Wambre E, et al. Grass-specific CD4(+) T-cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy. Clin Exp Allergy 2014;44:986-98
   PubMed Web of Science ®Google Scholar
• Hejl C, Wurtzen PA, Kleine-Tebbe J, et al. Phleum pratense alone is sufficient for allergen-specific immunotherapy against allergy to Pooideae grass pollens. Clin Exp Allergy 2009;39:752-9
   PubMed Web of Science ®Google Scholar
• Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract 2013;1:228-41
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124:471-7
   PubMed Web of Science ®Google Scholar
• Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6
   PubMed Web of Science ®Google Scholar
• Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011;128:559-66
   PubMed Web of Science ®Google Scholar
• Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012;130:1327-34
   PubMed Web of Science ®Google Scholar
• Study NCT00803244: Safety and efficacy of Phase III study on 300 IR SLIT in patients suffering from grass pollen rhinoconjunctivitis (with or without asthma). Stallergènes S.A., 2011. Available at http://clinicaltrials.gov/show/NCT00803244 [Last accessed 20 April 2014]
   Google Scholar
• Larsen TH, Poulsen LK, Melac M, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy–a phase-1 study. Allergy 2006;61:1173-6
   PubMed Web of Science ®Google Scholar
• Malling HJ, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009;39:387-93
   PubMed Web of Science ®Google Scholar
• Wahn U, Malling HJ, Cox LS, et al. Efficacy of 300IR 5-grass pollen extract sublingual tablet assessed by daily combined score: results of three double-blind placebo-controlled natural field studies in children/adolescents and adults. Presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting; Milan, Italy; 2013
   Google Scholar
• Howarth P, Malling HJ, Molimard M, Devillier P. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy 2012;67:321-7
   PubMed Web of Science ®Google Scholar
• Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317-24
   PubMed Web of Science ®Google Scholar
• Karagiannis E, et al. Non-interventional 2-year-study of sublingual immunotherapy in children and adolescents with allergic rhinoconjunctivitis caused by grass pollen. Presented at Pediatric Allergy & Asthma Meeting (PAAM); Athens, Greece; 2013
   Google Scholar
• Karagiannis E, Hadler M, Shah-Hosseini K, et al. Full symptom control in patients with allergic rhinoconjunctivitis caused by grass pollen - results of a 2-year sublingual allergen immunotherapy (AIT) study. Presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting; Milan, Italy; 2013
   Google Scholar
• Karagiannis E, Hadler M, Shah-Hosseini K, et al. Non-interventional 2-year study of sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by grass pollen. Presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting; Milan, Italy; 2013
   Google Scholar
• Antolin D, Valbuena T, Valls A, et al. One season of treatment with 5 grass pollen tablets in adults demonstrated a reduction in disease symptoms and impacts. Findings of the SMILE study. Presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting; Milan, Italy; 2013
   Google Scholar
• Fernandez-Nieto M, Alvarez JA, Alvarado MI, et al. What is the opinion of the patients under 5 grass pollen tablets immunotherapy? First season assessment in adults. Findings of the SMILE study. Presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting; Milan, Italy; 2013
   Google Scholar
• Halken S, Agertoft L, Seidenberg J, et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol 2010;21:970-6
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. J Eval Clin Pract 2014;20:225-38
   PubMed Web of Science ®Google Scholar
• Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ 2012;15:906-17
   PubMedGoogle Scholar
• Ruggeri M, Oradei M, Frati F, et al. Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults. Clin Drug Investig 2013;33:343-9
   PubMed Web of Science ®Google Scholar